Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
DAWN Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance with a 15% QoQ revenue increase and an 89% YoY growth, alongside strategic product developments and expansion plans. Despite some uncertainties in data maturity and profitability guidance, the company's solid cash position and reduced operating expenses highlight financial discipline. The Q&A session reflects management's cautious optimism, with positive updates on trial progress and market expansion. Given the market cap of approximately $1.2 billion, the stock is likely to react positively, with potential gains in the 2% to 8% range over the next two weeks.
Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance with a 10% increase in net product revenue and disciplined cost control. The Q&A section reveals positive sentiment towards new patient starts and physician confidence, supported by promising ASCO data. Despite some uncertainties in portfolio diversification and economic conditions, the company's strong cash position and strategic focus on OJEMDA provide a positive outlook. Given the market cap of $1.2 billion, the stock price is likely to see a positive movement of 2% to 8% over the next two weeks.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript
Positive5-7
The earnings call indicates positive financial performance with net revenue growth and better-than-expected EPS. The cash position is strong with no debt, reducing financing risks. The Q&A session confirms steady patient adoption and management's confidence in market positioning. Despite competitive pressures and regulatory challenges, the company's strategic focus on pipeline expansion and business development is promising. The positive sentiment is tempered slightly by management's lack of clarity on certain trial details, but overall, the financial health and strategic initiatives suggest a positive stock price movement in the short term.
DAWN Slides
DAWN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
